First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
Related Questions
How does NuCana's NUC-7738 pipeline progress compare to similar PD-1 resistant melanoma programs from competitors?
What are the projected financial implications of the expansion study on NuCana's Q3 and Q4 earnings guidance?
When is the next data readout expected for the NUC-7738 expansion study and how might it affect the stock price?